Posts

U.S. Launches Section 301 Investigation into Germany Over Drug Pricing and Unfair R&D Burden in 2026

on

Brand‑name drug prices keep climbing in the U.S. while falling abroad, amid push for MFN pricing: Report highlights

on

TrumpRx adds more than 600 generic meds, building on one success in US pricing

on

Novartis CEO Calls for 'Complete Rethink' on Europe's Drug Pricing Policies

on

Regeneron Among Remaining Holdouts in Trump's Most-Favored-Nation Drug Pricing Deals

on

White House Launches TrumpRx.gov as Key Pillar of Most Favored Nation Drug Pricing Deals

on

CMS Selects Trulicity and Biktarvy Among 15 Drugs for Third Medicare Price Negotiation Cycle

on

Trump Unveils 'The Great Healthcare Plan' to Lower Drug Prices and Target Insurers

on

Drugmakers with White House MFN Deals Claim Exemption from Proposed Medicare Pricing Tests

on

White House unveils nine new “most-favored-nation” drug pricing deals

on

UK cuts 2026 new-medicine rebate rate to 14.5% under VPAG

on

CMS Unveils Negotiated Prices for Ozempic, Wegovy, and Other Drugs in Second Round of IRA Talks

on

Pharma Faces Supreme Court Deadline as IRA Price Negotiation Takes Effect

on

Weight-loss Drugs Lead Latest Batch of FDA Priority Voucher Recipients

on

Trump Announces Sweeping Cost Cuts on Lilly and Novo Weight Loss Drugs in Exchange for Medicare Coverage

on

Lilly and Novo Nordisk Near White House Deal to Cut Obesity Drug Prices

on

Cigna Announces End to Drug Rebates for Many Health Plans Beginning in 2027

on

Roche in Talks With US on Drug Pricing; Sets Out Pipeline and Dealmaking Ambitions

on

Weight-loss drug stocks drop after Trump pledges major price cuts

on

White House Announces New Most-Favored Nation Drug Pricing Deal, Updates on FDA Vouchers and GLP-1 Negotiations

on